Search clinical trials for: Daratumumab

Total 321 results

Peking University People's Hospital

Recruiting

Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients With MIDD

Monoclonal Gammopathy of Renal Significance

China
Kite, A Gilead Company
Arcellx, Inc.

Not yet recruiting

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3)

Multiple Myeloma
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
Sidney Kimmel Comprehensive Cancer Center at Johns...
Janssen Research & Development, LLC

Not yet recruiting

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Myelofibrosis | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Hematologic Malignancy | Aplastic Anemia | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Bone Marrow Transplant Rejection | Acute Lymphoblastic Leukemia (ALL), Adult
Nanjing University School of Medicine

Recruiting

Daratumumab for Patients With Light Chain Amyloidosis

Light Chain (AL) Amyloidosis

China
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults

Tumor

China
Children's National Research Institute
The Hospital for Sick Children; Ann & Robert H Lurie Children's Hospital of... and other collaborators

Recruiting

Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodY (SUN-RAY)

Sickle Cell Disease

United States
Nantes University Hospital
Janssen Pharmaceutica

Not yet recruiting

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (IFm2022-01)

Multiple Myeloma

France
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Multiple Myeloma | Newly Diagnosed Multiple Myeloma | Autologous Stem Cell Transplantation

United States
Beijing Chao Yang Hospital
Beijing Boren Hospital; Beijing Chuiyangliu Hospital

Not yet recruiting

Combination of Daratumumab and BD Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease

M-protein Related Cardiac Disease
Biocad

Recruiting

A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma (DARVIVA)

Multiple Myeloma

Russian Federation
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Not yet recruiting

Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program (DARATALL-VHR)

T-Lymphocytic Leukemia, Acute
Celgene

Not yet recruiting

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ALUMMINATE)

Multiple Myeloma

China, Australia, United States, Argentina, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Norway, Portugal, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
Jin Lu, MD

Recruiting

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

AL Amyloidosis | Amyloidosis; Systemic

China
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS (TAURUS)

Multiple Myeloma

Austria, Greece, Italy, Netherlands, Germany
Stichting Hemato-Oncologie voor Volwassenen Nederland

Not yet recruiting

FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) (HOVON174MM)

Multiple Myeloma
Canadian Cancer Trials Group
Canadian Institutes of Health Research (CIHR); Myeloma Canada

Recruiting

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada
National Cancer Institute (NCI)

Recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
University of Pennsylvania

Not yet recruiting

CD40 Agonist and PD-1 Inhibitor in HNSCC

Head and Neck Squamous Cell Carcinoma
Institute of Hematology & Blood Diseases Hospital...

Recruiting

DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

Multiple Myeloma

China
Wuhan Union Hospital, China

Recruiting

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Extramedullary Multiple Myeloma | Primary Plasma Cell Leukemia

China
Augusta University
Janssen Scientific Affairs, LLC

Not yet recruiting

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

Multiple Myeloma | Renal Failure

United States
Indapta Therapeutics, INC.

Recruiting

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Multiple Myeloma | Refractory Multiple Myeloma | Refractory Non-Hodgkin Lymphoma | NHL | Blood Cancer | Relapsed Multiple Myeloma | Relapsed Non-Hodgkin Lymphoma

United States
Barbara Ann Karmanos Cancer Institute
Bristol-Myers Squibb; Janssen Pharmaceuticals; Multiple Myeloma Research Consortium

Recruiting

Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma (IBEX)

Multiple Myeloma

United States
Carl Ola Landgren, MD, PhD
Janssen Scientific Affairs, LLC

Recruiting

Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study) (REVIVE)

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
Janssen Pharmaceuticals

Recruiting

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Multiple Myeloma | Monoclonal Gammopathy of Renal Significance

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Korea, Republic of, Denmark, Spain, Australia, Italy, New Zealand, France, Canada, Germany
Georgetown University
Janssen, LP

Recruiting

Daratumumab for Polyneuropathy Associated With MGUS (Dara-MGUS)

Monoclonal Gammopathy of Undetermined Significance | Peripheral Neuropathy

United States
Mayo Clinic

Recruiting

Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Multiple Myeloma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

AL Amyloidosis
Georgetown University
Bristol-Myers Squibb; Targovax ASA; Janssen, LP

Recruiting

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer (DARANIVOVAX)

Pancreatic Ductal Adenocarcinoma | Refractory Non-Small Cell Lung Cancer

United States
First Affiliated Hospital of Zhejiang University

Recruiting

The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation

Antibody-mediated Rejection | Kidney Tranplant

China
National Cancer Institute (NCI)

Recruiting

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma

Lymphoma, Primary Effusion

United States
Mayo Clinic

Recruiting

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

AL Amyloidosis

United States
Carl Ola Landgren, MD, PhD
Bristol-Myers Squibb

Recruiting

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma (Iber-KDd)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Institute of Hematology & Blood Diseases Hospital...
Sinocelltech Ltd.

Recruiting

ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

Hemophilia A With Inhibitor

China
Second Affiliated Hospital of Soochow University
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A (AHA2023)

Acquired Hemophilia

China
PETHEMA Foundation
Janssen Pharmaceutica

Recruiting

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (GEM-TECTAL)

High-Risk de Novo Multiple Myeloma

Spain
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients. (DILEMMA)

Multiple Myeloma | Daratumumab | Autologous Stem Cell Transplantation | Leukapheresis

Italy
Institute of Hematology & Blood Diseases Hospital

Recruiting

Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients With Aplastic Anemia

Aplastic Anemia | Platelet Transfusion Refractoriness

China
NYU Langone Health

Recruiting

Daratumumab in STK11 Mutated NSCLC

Non-small Cell Lung Cancer With STK11/LKB1 Mutation

United States
Air Force Military Medical University, China

Not yet recruiting

Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis

Immunoglobulin Light-chain Amyloidosis
Nantes University Hospital

Not yet recruiting

Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM) (DARALAM)

Adult Patients With Adverse Risk Acute Myeloblastic Leukemia
Istituto Giannina Gaslini

Recruiting

Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome

Nephrotic Syndrome

Italy
University of Heidelberg Medical Center
Janssen Research & Development, LLC; Deutsche Studiengruppe Multiples Myelom...

Recruiting

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (HD10/DSMMXX)

Multiple Myeloma

Germany
Universitätsklinikum Hamburg-Eppendorf
Gemeinsamer Bundesausschuss (G-BA); Staburo GmbH

Recruiting

Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy (AlloRelapseMM)

Multiple Myeloma

Germany
National Institute of Allergy and Infectious Diseases...
PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)

Recruiting

Daratumumab in Primary Antiphospholipid Syndrome (DARE-APS)

Autoimmune Disorders

United States
Mayo Clinic

Recruiting

Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits

Proliferative Glomerulonephritis With Monoclonal IgG Deposits

United States

Search clinical trials for: Daratumumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations